“Galapagos has built extensive expertise in using RNAi to discover and validate novel drug targets in a wide range of disease areas. Our scientists were invited to present our protein knock-down technology using adenovirus-based RNAi libraries to discover new targets in human primary cells,” said Onno van de Stolpe, CEO of Galapagos. “There is particularly strong interest in RNAi in the pharmaceutical industry and we believe targets identified using our approach could improve overall success rates in the drug discovery process. The confidence is underscored by the fact that our pharmaceutical partners have taken targets identified using this biology-driven strategy, forward into their internal drug discovery programs.”
Galapagos is a publicly traded, genomics-based drug discovery company (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA) that has successfully discovered and validated novel targets in the bone and joint diseases – osteoarthritis, osteoporosis and rheumatoid arthritis, as well as in asthma and Alzheimer’s disease. Proprietary targets and compounds resulting from these programs are used for Galapagos’ internal drug discovery programs, combined with selected out-licensing and partnering of projects during development.
More information about Galapagos can be found at www.glpg.com.